Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gottlieb: Real Risk Of Congressional Action If Anti-Competitive Actions Continue

Executive Summary

To remain shielded from political forces that could change incentives, pharmaceutical industry must adopt 'a certain set of values,' US FDA Commissioner says.

You may also be interested in...



Gottlieb Tells Brand Firms To Sell Samples For Generics – Or Face The Consequences

The idea could help quiet growing criticism over system gaming and high drug prices.

Lyrica Generics Were Likely Delayed By A Pfizer Labeling Supplement

US FDA's last-minute approval may have allowed Pfizer three more weeks of sales without competition.

Lyrica Generics Likely Delayed By A Pfizer Labeling Supplement

US FDA's last-minute approval may have allowed Pfizer three more weeks of sales without competition.

Related Content

Topics

UsernamePublicRestriction

Register

PS123036

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel